{'fraction_non_alphanumeric': 0.010962241169305725, 'fraction_numerical': 0.00243605359317905, 'mean_word_length': 5.180451127819549, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Plasma phosphate and potassium levels in the hypercalcemia of malignant disease.

In a series of 28 cases of hypercalcemia associated with malignant disease, hypophosphatemia was the rule when the level of blood urea was taken into account: hyperphosphatemia did not occur. In this respect no difference could be demonstrated between subjects with mammary carcinoma and those with extensive osseous metastases, when compared with those with malignant disease in other tissues and those without bony involvement. It is suggested that the case for mechanical breakdown of bone by metastases and for osteolytic sterols as causes of the hypercalcemia of malignancy is not proven, and that in all subjects it could be due to production of parathyroid or a similar hormone by the tumor. Other possible mechanisms are discussed.